Eyenovia Reports Q3 2024 Results: Clobetasol Launch and Myopia Program Advance
Key Insights
Eyenovia launched clobetasol propionate ophthalmic suspension 0.05% in the U.S. for post-operative inflammation, marking the first new ocular steroid in over 15 years.
The company is advancing its Phase 3 CHAPERONE study for MicroPine in pediatric myopia (search), with an interim analysis expected this quarter.
Mydcombi's reach expanded to 230 new offices between April and September 2024, demonstrating steady market penetration.
Eyenovia, Inc. (NASDAQ: EYEN) announced its financial and operating results for the third quarter ended September 30, 2024, highlighting the U.S. launch of clobetasol propionate ophthalmic suspension 0.05% and progress in its MicroPine pediatric myopia (search) program. The company's strategic advancements in ophthalmic solutions aim to address significant market needs, even as financial results reflect increased operational investments.
Commercial Expansion and Product Launches
Michael Rowe, Chief Executive Officer of Eyenovia, emphasized the significance of the clobetasol launch, noting it as the first new ocular steroid approved in over 15 years. "Clobetasol perfectly complements our mydriasis product, Mydcombi, and allows us to further leverage our sales force while adding significant value to eye doctors and surgeons," Rowe stated. The company also reported expanding Mydcombi's reach to 230 new offices between April and September 2024.
Advancing Pediatric Myopia Treatment
Eyenovia is currently advancing its Phase 3 CHAPERONE study of MicroPine for pediatric progressive myopia (search). The company anticipates an interim data analysis this quarter, which, if successful, could accelerate the remaining development path. Rowe noted the significant market potential, stating, "Together, these indications represent multi-billion-dollar addressable markets in the U.S. alone."
Financial Overview
For the third quarter of 2024, Eyenovia reported a net loss of approximately $7.9 million, or $0.11 per share, compared to a net loss of $7.3 million, or $0.18 per share, for the third quarter of 2023. Research and development expenses totaled approximately $3.5 million, consistent with the $3.6 million reported for the same period in 2023. Selling, general, and administrative expenses increased by 27.3% to $3.7 million, reflecting the establishment of the company’s sales force. As of September 30, 2024, Eyenovia’s unrestricted cash and cash equivalents were approximately $7.2 million, with the company actively evaluating long-term financing options.
Strategic Collaborations and Pipeline Development
Eyenovia has also entered into co-development agreements to evaluate novel therapeutics using its Optejet dispenser for potential treatments for dry eye disease (search), targeting a $5 billion global market. The company has commenced manufacturing registration batches of Mydcombi in its second-generation Optejet device, a crucial step toward FDA approval, potentially expected in 2026.
Future Outlook
Looking ahead, Eyenovia is focused on advancing its pipeline, leveraging its Optejet technology, and expanding its commercial footprint. "With two differentiated commercial products, another in late Phase 3 development, multiple opportunities in dry eye, and the advanced Gen-2 Optejet technology platform, I believe we are creating a foundation from which we can drive significant growth and value creation in the months and years to come," concluded Mr. Rowe.